论文部分内容阅读
慢性粒细胞白血病（ＣＭＬ）主要;因为细胞的凋亡受抑制而致病，其特征性的遗传学改变是９号与２２号染色体间的易位并形成 Ｐｈ染色体，该易位产生一个 ＢＣＲ／ＡＢＬ融合基因，其表达产物为具有高酪氨酸激酶活性的 ＢＣＲ／ＡＢＬ融合蛋白 Ｐ２１０ＢＣＲ，ＡＢＬ，后者被认为是 ＣＭＬ发病的分子基础。本文综述了 Ｐ２１０ＢＣＲ／ＡＢＬ融合蛋白通过抑制骨髓前体细胞的凋亡而在ＣＡＬ发病中起重要作用，并由此推测酪氨酸激酶抑制剂除莠霉素（herbimycin A）在ＣＭＬ的治疗中可能具有广阔的应用前景。
Chronic myeloid leukemia (CML) is predominant; the disease is characterized by inhibition of apoptosis and its characteristic genetic alteration is the translocation between chromosomes 9 and 22 and the formation of a Ph chromosome that produces a BCR / ABL fusion gene, whose expression product is BCR / ABL fusion protein P210BCR with high tyrosine kinase activity, ABL, which is considered as the molecular basis for the pathogenesis of CML. This review summarizes that P210BCR / ABL fusion protein plays an important role in the pathogenesis of CAL by inhibiting the apoptosis of bone marrow progenitor cells, and thus infer that the tyrosine kinase inhibitor herbimycin A may be involved in the treatment of CML have a broad vision of application.